Trial · NCT02697630
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
NCT02697630, Phase 2, Completed, Vastra Gotaland Region
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye. Trials, record NCT02697630. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02697630
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
- NCT number
- NCT02697630
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Vastra Gotaland Region
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- Pembrolizumab, Entinostat
- First posted
- 2016-03-03
- Last updated
- 2023-12-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From first dose up to 24 months | The proportion of patients that have a best overall response of complete response (CR) or partial response (PR), as assessed by RECIST 1.1. |
| Secondary | Clinical benefit rate (CBR) | 18 weeks from first dose | |
| Secondary | Progression free survival (PFS) | From first dose up to 24 months | |
| Secondary | Overall Survival (OS) | From first dose up to 24 months | |
| Secondary | Best overall response (BOR) | From first dose up to 24 months | |
| Secondary | Time To Response (TTR) | From first dose up to 24 months | |
| Secondary | Duration of objective response (DOR) | From first dose up to 24 months | |
| Secondary | Adverse Events (AEs) and Serious Adverse Events (SAEs). | From first dose up to 24 months | Incidence and severity |
| Secondary | Eastern Cooperative Oncology Group (ECOG) Performance status (PS) | 18 weeks from first dose | |
| Secondary | Quality of Life (QoL) assessed by FACT-G | From first dose up to 24 months |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02697630
GET https://conductscience.org/api/trials/v1/NCT02697630/registered